News on CytRx from BioPortfolio.com http://www.BioPortfolio.com Consolidated CytRx news from BioPortfolio.com Wed, 10 Feb 2010 13:36:20 GMT en Form SC 13G/A RXI PHARMACEUTICALS CORP Filed by: CYTRX CORPhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007003&HITNO=0&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007003&THISHREF=http://c.moreover.com/click/here.pl%3fz2520965339%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007003&HITNO=0&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007003&THISHREF=http://c.moreover.com/click/here.pl%3fz2520965339%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: RECOTHROM topical hemostat has low rate of anti-product antibody formation and is well-toleratedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997139&HITNO=1&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997139&THISHREF=http://c.moreover.com/click/here.pl%3fz2516577200%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997139&HITNO=1&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997139&THISHREF=http://c.moreover.com/click/here.pl%3fz2516577200%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: CytRx to Present at the 12th Annual BIO CEO & Investor Conferencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991496&HITNO=2&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991496&THISHREF=http://c.moreover.com/click/here.pl%3fz2513729444%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991496&HITNO=2&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991496&THISHREF=http://c.moreover.com/click/here.pl%3fz2513729444%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: CytRx to Present at the 12th Annual BIO CEO & Investor Conferencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992774&HITNO=3&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992774&THISHREF=http://c.moreover.com/click/here.pl%3fz2514324122%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992774&HITNO=3&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992774&THISHREF=http://c.moreover.com/click/here.pl%3fz2514324122%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: In Court Filing, Alnylam, Max Planck Question UMass Ownership of Tuschl-I IPhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3967289&HITNO=4&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3967289&THISHREF=http://c.moreover.com/click/here.pl%3fz2499573484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3967289&HITNO=4&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3967289&THISHREF=http://c.moreover.com/click/here.pl%3fz2499573484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenomeWeb: CytRx Announces 2010 Clinical and Development Milestoneshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3963799&HITNO=5&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3963799&THISHREF=http://c.moreover.com/click/here.pl%3fz2497864489%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3963799&HITNO=5&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3963799&THISHREF=http://c.moreover.com/click/here.pl%3fz2497864489%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: CytRx Announces 2010 Clinical and Development Milestoneshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3947594&HITNO=6&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3947594&THISHREF=http://c.moreover.com/click/here.pl%3fz2488169794%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3947594&HITNO=6&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3947594&THISHREF=http://c.moreover.com/click/here.pl%3fz2488169794%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: CytRx announces its plans to advance multiple oncology development programs in 2010http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3947354&HITNO=7&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3947354&THISHREF=http://c.moreover.com/click/here.pl%3fz2488008493%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3947354&HITNO=7&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3947354&THISHREF=http://c.moreover.com/click/here.pl%3fz2488008493%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: CytRx Announces 2010 Clinical and Development Milestoneshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3944231&HITNO=8&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3944231&THISHREF=http://c.moreover.com/click/here.pl%3fz2486425936%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3944231&HITNO=8&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3944231&THISHREF=http://c.moreover.com/click/here.pl%3fz2486425936%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: CytRx Announces 2010 Clinical and Development Milestoneshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3942661&HITNO=9&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3942661&THISHREF=http://c.moreover.com/click/here.pl%3fz2485833793%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3942661&HITNO=9&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3942661&THISHREF=http://c.moreover.com/click/here.pl%3fz2485833793%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 as a Treatment for Advanced Pancreatichttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3928279&HITNO=10&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3928279&THISHREF=http://c.moreover.com/click/here.pl%3fz2479187300%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3928279&HITNO=10&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3928279&THISHREF=http://c.moreover.com/click/here.pl%3fz2479187300%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: RXi Pharmaceuticals Talks Partnershipshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3922136&HITNO=11&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3922136&THISHREF=http://c.moreover.com/click/here.pl%3fz2475690715%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3922136&HITNO=11&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3922136&THISHREF=http://c.moreover.com/click/here.pl%3fz2475690715%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCafepharma: RXi Pharmaceuticals Talks Partnershipshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3917913&HITNO=12&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3917913&THISHREF=http://c.moreover.com/click/here.pl%3fz2472507621%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3917913&HITNO=12&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3917913&THISHREF=http://c.moreover.com/click/here.pl%3fz2472507621%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSeeking Alpha: CytRx To Conduct Phase 2 Clinical Trial With Bafetinib In B-cell Chronic Lymphocytic Leukemiahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911743&HITNO=13&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911743&THISHREF=http://c.moreover.com/click/here.pl%3fz2469852031%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911743&HITNO=13&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911743&THISHREF=http://c.moreover.com/click/here.pl%3fz2469852031%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMediLexicon: CytRx To Conduct Phase 2 Clinical Trial With Bafetinib In B-cell Chronic Lymphocytic Leukemiahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911346&HITNO=14&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911346&THISHREF=http://c.moreover.com/click/here.pl%3fz2469526874%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911346&HITNO=14&MSIZE=57&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CytRx&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911346&THISHREF=http://c.moreover.com/click/here.pl%3fz2469526874%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: